Asian pharmaceutical stocks rebound as Trump's drug price reduction executive order is vague in wording and weaker than expected in strength.

Concerns sparked by President Donald Trump's executive order to lower prescription drug prices in the United States have eased, leading to a rebound in the stock prices of Asian pharmaceutical companies. Analysts say that implementing the executive order will be very difficult. Trump's goal is to get pharmaceutical companies to come to the negotiating table, and the executive order he signed on Monday asks them to voluntarily lower prices or face regulatory measures. Analysts believe the order is vague and less forceful than what pharmaceutical companies had initially expected. In the Japanese market, Daiichi Sankyo rose by 7.8%, Takeda Pharmaceuticals by 4.7%, Astellas Pharma by 4.8%, and Nichi-Iko by 2.9%. In South Korea, Celltrion rose by 3%, SK Biopharmaceuticals by 5.9%, and Yuhan by 4.2%. In Australia, Telix Pharmaceuticals rose by 6.3% and CSL by 3.4%. In India, Sun Pharma rose by 3.7% and Lupin by 3.3%.